Lanreotide
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Lanreotide: From Somatostatin-Analog Therapy to Hypertrichosis
One-Sentence Summary
Lanreotide is a long-acting somatostatin analog; per available background it is used to suppress growth hormone/IGF-1 secretion in conditions such as acromegaly and neuroendocrine tumours (formal indication text is not available in this evidence pack). The TxGNN model predicts it may be effective for hypertrichosis (disease), but this prediction is currently supported by 0 clinical trials and 0 publications, and no mechanistic link between somatostatin receptor signalling and hair growth pathways has been established.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — drug is not marketed in New Zealand and no license/indication text exists; per repurposing-rationale notes, lanreotide is clinically used for acromegaly and neuroendocrine tumours |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| New Zealand Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a Blocking/High-severity data gap). Based on the limited background information present in this evidence pack, lanreotide belongs to the somatostatin-analog class, understood to suppress growth hormone (GH) and IGF-1 secretion, and is used clinically in conditions such as acromegaly and neuroendocrine tumours.
Hypertrichosis (excessive hair growth) has no established pathophysiological connection to somatostatin receptor signalling. The repurposing rationale attached to this candidate explicitly notes that no known mechanistic link exists between the two, and the prediction is generated purely from TxGNN's embedding-based similarity score, without any corroborating clinical trial or literature evidence.
Given the complete absence of supporting data (0 trials, 0 publications) and the missing original-indication/MOA data needed for cross-validation, this prediction should be treated as a low-confidence model output rather than a mechanistically grounded hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
New Zealand Market Information
Lanreotide is not marketed in New Zealand (0 authorizations on record); no product/license data is available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (hypertrichosis) has no clinical trials, no literature support, and no plausible mechanistic link to lanreotide's somatostatin-agonist activity — it is a pure model-score output (L5) and does not meet the threshold for further evaluation. Note: the four other TxGNN-ranked candidates in this evidence pack (periodontal/odontal malformation syndrome, Dandy-Walker-related syndrome, isolated genetic hair shaft abnormality, Ambras-type congenital hypertrichosis) are similarly unsupported — the one candidate with literature hits (20 PubMed records on periodontitis) was reviewed and found to be keyword-matched noise unrelated to lanreotide, not genuine evidence.
To proceed, the following is needed:
- Confirmed original indication(s) and detailed MOA for lanreotide (currently Blocking/High data gaps)
- TFDA/regulatory package insert (warnings, contraindications) — currently unavailable
- A biologically plausible mechanistic hypothesis linking somatostatin receptor pathways to hypertrichosis before any further screening investment
- If pursuing this candidate further, targeted literature/trial searches using lanreotide-specific terms combined with hair-growth/dermatology MeSH terms, since the current PubMed pull returned no direct hits
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.